A new trading day began on Monday, with Xilio Therapeutics Inc (NASDAQ: XLO) stock price up 6.68% from the previous day of trading, before settling in for the closing price of $0.8. XLO’s price has ranged from $0.62 to $1.70 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -11.55% over the past five years. Meanwhile, its annual earnings per share averaged 58.72%. With a float of $22.39 million, this company’s outstanding shares have now reached $51.83 million.
Xilio Therapeutics Inc (XLO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Xilio Therapeutics Inc is 56.79%, while institutional ownership is 18.99%. The most recent insider transaction that took place on Jun 16 ’25, was worth 30,870. In this transaction Director of this company bought 45,000 shares at a rate of $0.69, taking the stock ownership to the 45,000 shares. Before that another transaction happened on Jun 17 ’25, when Company’s Director bought 25,000 for $0.69, making the entire transaction worth $17,215. This insider now owns 70,000 shares in total.
Xilio Therapeutics Inc (XLO) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.22 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.19% during the next five years compared to -11.55% drop over the previous five years of trading.
Xilio Therapeutics Inc (NASDAQ: XLO) Trading Performance Indicators
Here are Xilio Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of Xilio Therapeutics Inc (XLO)
Xilio Therapeutics Inc (NASDAQ: XLO) saw its 5-day average volume 1.2 million, a negative change from its year-to-date volume of 1.75 million. As of the previous 9 days, the stock’s Stochastic %D was 52.82%.
During the past 100 days, Xilio Therapeutics Inc’s (XLO) raw stochastic average was set at 79.69%, which indicates a significant increase from 71.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0594 in the past 14 days, which was higher than the 0.0396 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7697, while its 200-day Moving Average is $0.7736. Nevertheless, the first resistance level for the watch stands at $0.8867 in the near term. At $0.9233, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9667. If the price goes on to break the first support level at $0.8067, it is likely to go to the next support level at $0.7633. Assuming the price breaks the second support level, the third support level stands at $0.7267.
Xilio Therapeutics Inc (NASDAQ: XLO) Key Stats
With a market capitalization of 44.05 million, the company has a total of 51,828K Shares Outstanding. Currently, annual sales are 6,340 K while annual income is -58,240 K. The company’s previous quarter sales were 8,080 K while its latest quarter income was -15,840 K.
